Since 2016, with the introduction of Iranian nanomedicines to the domestic market and the replacement of some foreign drugs with these locally produced nanomedicines, insurance companies have reduced their costs by about 11.7 million dollars. This amount is approximately 1.9 times the domestic sales of three nanomedicines: Sinadoxosome, Padynex, and Paclinab.

Furthermore, with the introduction of these three Iranian nanomedicines, not only have prices decreased and patient access been facilitated, but 90 million dollars in foreign currency has also been saved. The domestic market sales of the three locally produced nanomedicines, namely Sinadoxosome, Paclinab, and Padynex, amounted to approximately 6 million dollars from 2016 to 2022. During these years, exports of these drugs to regional countries, including Turkey and Syria, exceeded 15 thousand dollars. The foreign exchange savings resulting from the replacement of these drugs are ten times their export value, amounting to more than 150 thousand dollars.

Sinadoxosome is an anti-tumor drug used in the treatment of metastatic breast cancer, especially in patients exposed to or having heart problems, as well as in the treatment of advanced ovarian cancer. This drug is also used in the treatment of Kaposi's sarcoma in AIDS patients.

The anti-cancer nanomedicine Paclinab is produced for the treatment of cancers such as breast, lung, and pancreas. This nanomedicine, by penetrating cancerous tissue, prevents tumor progression and leads to the destruction of cancerous tissue. Due to its nanoscale dimensions, this drug has higher efficacy and fewer side effects compared to similar drugs.

Padynex is a pioneering targeted therapy for treating specific types of cancer. This drug, by combining an antibody with a chemotherapy agent, provides a more targeted and effective approach to cancer treatment. This targeted approach increases the drug's efficacy and reduces side effects compared to traditional chemotherapy.